Newron Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Newron Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 51.2% bzw. 39.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 51.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 143% betragen.

Wichtige Informationen

51.2%

Wachstumsrate der Gewinne

51.1%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	11.4%
Wachstumsrate der Einnahmen	39.2%
Zukünftige Eigenkapitalrendite	143.0%
Analystenabdeckung	Low
Zuletzt aktualisiert	27 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Apr 11

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

Nov 06

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Apr 06

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Apr 01

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

Feb 25

Gewinn- und Umsatzwachstumsprognosen

SWX:NWRN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	43	23	31	31	2
12/31/2025	27	5	14	14	3
12/31/2024	37	15	29	28	3
12/31/2023	9	-16	-10	-10	N/A
9/30/2023	9	-16	-11	-11	N/A
6/30/2023	9	-16	-11	-11	N/A
3/31/2023	7	-17	-11	-11	N/A
12/31/2022	6	-17	-11	-11	N/A
9/30/2022	6	-16	-10	-10	N/A
6/30/2022	6	-14	-8	-8	N/A
3/31/2022	6	-15	-10	-10	N/A
12/31/2021	6	-15	-11	-11	N/A
9/30/2021	6	-17	-14	-14	N/A
6/30/2021	5	-20	-17	-17	N/A
3/31/2021	5	-20	-16	-16	N/A
12/31/2020	5	-21	-16	-16	N/A
9/30/2020	6	-19	-15	-15	N/A
6/30/2020	7	-17	-14	-14	N/A
3/31/2020	7	-18	-18	-18	N/A
12/31/2019	7	-20	-22	-22	N/A
9/30/2019	6	-21	-22	-22	N/A
6/30/2019	4	-21	-21	-21	N/A
3/31/2019	4	-18	-19	-19	N/A
12/31/2018	4	-15	-16	-16	N/A
9/30/2018	4	-15	-16	-16	N/A
6/30/2018	4	-14	-16	-16	N/A
3/31/2018	9	-10	-12	-12	N/A
12/31/2017	13	-5	-8	-8	N/A
9/30/2017	14	-5	N/A	-10	N/A
6/30/2017	15	-5	N/A	-12	N/A
3/31/2017	11	-10	N/A	-16	N/A
12/31/2016	7	-15	N/A	-20	N/A
9/30/2016	6	-20	N/A	-18	N/A
6/30/2016	4	-25	N/A	-17	N/A
3/31/2016	3	-24	N/A	-15	N/A
12/31/2015	2	-23	N/A	-13	N/A
9/30/2015	2	-18	N/A	-12	N/A
6/30/2015	2	-12	N/A	-11	N/A
3/31/2015	2	-11	N/A	-10	N/A
12/31/2014	2	-10	N/A	-10	N/A
9/30/2014	2	-10	N/A	-9	N/A
6/30/2014	3	-9	N/A	-8	N/A
3/31/2014	3	-8	N/A	-9	N/A
12/31/2013	4	-7	N/A	-11	N/A
9/30/2013	4	-7	N/A	-9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NWRN wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (0.2%).

Ertrag vs. Markt: NWRN wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: NWRN wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: NWRNDie Einnahmen des Unternehmens (39.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swiss (4.4% pro Jahr).

Hohe Wachstumseinnahmen: NWRNDie Einnahmen des Unternehmens (39.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: NWRNDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (143%).

Newron Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast breakeven date pushed back to 2026

Consensus revenue estimates fall by 19%

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2023

Forecast breakeven date moved forward to 2023

Recent updates

Newron Pharmaceuticals S.P.A Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

Forecast breakeven date pushed back to 2026

Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients

Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Consensus revenue estimates fall by 19%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Forecast breakeven date pushed back to 2025

Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia (TRS)

Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide

Newron Pharmaceuticals S.p.A. to Report Fiscal Year 2023 Results on Mar 19, 2024

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2023

Newron Pharmaceuticals S.P.A. Presents New Data from Study 014/015 Evaluating Its Investigational Drug Evenamide for the Management of Treatment Resistant Schizophrenia

Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor

New minor risk - Market cap size

Forecast breakeven date moved forward to 2023

Full year 2022 earnings released: €0.98 loss per share (vs €0.83 loss in FY 2021)

Newron Reports Striking One-Year Interim Efficacy Results from Its Phase Ii Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia

Newron Pharmaceuticals S.p.A. Announces Striking Six-Month Interim Results from Its Exploratory Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 18, 2023

Insufficient new directors

First half 2022 earnings released: €0.48 loss per share (vs €0.51 loss in 1H 2021)

Newron Pharmaceuticals S.P.A. Presents Encouraging Interim Results for Evenamide in Patients with Treatment-Resistant Schizophrenia (Trs) At the 33Rd Cinp Hybrid World Congress of Neuropsychopharmacology

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

First half 2021 earnings released: €0.51 loss per share (vs €0.59 loss in 1H 2020)

Newron Pharmaceuticals S.p.A. Announces Paragraph IV ANDA Filings for Xadago® (safinamide) in the USA

Newron Pharmaceuticals S.p.A. Announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2020 earnings released: €1.18 loss per share (vs €1.13 loss in FY 2019)

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 13, 2021

Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson’s Disease Patients

New 90-day high: CHF2.99

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

New 90-day high: CHF2.95

Newron Pharmaceuticals Completes Enrollment of Explanatory Safety and Efficacy Study with Evenamide in Schizophrenia Patients

New 90-day high: CHF2.25

New 90-day high: CHF2.11

Analysts lower EPS estimates to -€1.17

First half earnings released

New 90-day low - CHF1.55

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken